Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10926074 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL9501105 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL19474824 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL19593693 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL8825927 | 0.95 | MGLL (0.38) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL17603026 | 0.95 | MGLL (0.38) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL14433301 | 0.95 | MGLL (0.38) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL13835372 | 0.95 | MGLL (0.38) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL12912977 | 0.95 | MGLL (0.38) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL514846 | 0.94 | MGLL (0.33) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023278649-A1 | STABILIZED UV ACTIVE ORGANOPALLADIUM COMPOUNDS AS VINYL ADDITION CATALYSTS | PROMERUS, LLC (US) | 2023-01-05 | — | — | WO | claimed |
| EP-0041175-B2 | ION SPECIFIC ANALYTICAL ELEMENT | MILES INC. (US) | 1993-06-09 | — | — | EP | claimed |
| EP-0119431-B1 | METHOD OF PREPARING ERYTHROMYCIN A CYCLIC 11,12-CARBONATE | Tarchominskie Zaklady Farmaceutyczne "Polfa" (PL) | 1987-09-16 | — | — | EP | claimed |
| EP-0041175-B1 | ION SPECIFIC ANALYTICAL ELEMENT | MILES INC. (US) | 1985-11-21 | — | — | EP | claimed |
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-20160022842-A1 | FORMATION AND USES OF EUROPIUM | WAYNE STATE UNIVERSITY (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2164327-A2 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009025914-A2 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20070180688-A1 | METHOD FOR PRODUCING A LITHIUM SECONDARY BATTERY | CANON KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| US-7081320-B2 | High energy density secondary battery for repeated use | CANON KABUSHIKI KAISHA (JP) | 2006-07-25 | — | — | US | disclosed |
| US-6391492-B1 | OXIDATION OF TITANIUM, VANADIUM, CHROMIUM, MANGANESE, IRON, COBALT, NICKEL OR COPPER BY REACTION TRANSITION METAL COMPOUND WITH WATER, ALCOHOL, OR HYDROXIDE; LITHIUM BATTERIES; DURABILITY | CANON KABUSHIKI KAISHA (JP) | 2002-05-21 | — | — | US | disclosed |
| US-6207326-B1 | ANODES AND CATHODES WITH NITROGEN AND HALOGEN | CANON KABUSHIKI KAISHA (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0119431-B1 | METHOD OF PREPARING ERYTHROMYCIN A CYCLIC 11,12-CARBONATE | Tarchominskie Zaklady Farmaceutyczne "Polfa" (PL) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | FGFR1, PDGFRA, KIF18B | MGLL 4062/4885CA1 325/4885CA2 367/4885 |
| US-20160022842-A1 | FORMATION AND USES OF EUROPIUM | LETM1, CECR2, MCU | MGLL 58/4885CA1 1037/4885CA2 1081/4885 |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | FGFR1, PDGFRA, KIF18B | MGLL 4062/4885CA1 325/4885CA2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.